UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, focusing on innovative treatments for severe diseases in immunology and neurology.
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)